John Bilezikian

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. pmc Therapy of osteoporosis in men with teriparatide
    Natalie E Cusano
    Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University in the City of New York, New York, NY 10032, USA
    J Osteoporos 2011:463675. 2011
  2. pmc Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series
    Natalie E Cusano
    MD, Department of Medicine, PH 8W 864, Columbia University College of Physicians and Surgeons, 630 West 168th Street, PH8W, Room 864, New York, New York 10032
    J Clin Endocrinol Metab 98:4285-90. 2013
  3. pmc Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations
    Natalie E Cusano
    Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:2734-41. 2013
  4. pmc The effect of PTH(1-84) on quality of life in hypoparathyroidism
    Natalie E Cusano
    Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:2356-61. 2013
  5. pmc Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism
    Barbara Campolina Silva
    Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:1963-70. 2013
  6. doi request reprint Primary hyperparathyroidism
    John P Bilezikian
    Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Endocr Pract 18:781-90. 2012
  7. pmc Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety
    Natalie E Cusano
    Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:137-44. 2013
  8. ncbi request reprint Parathyroid hormone as an anabolic therapy for women and men
    J P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Endocrinol Invest 28:41-9. 2005
  9. pmc Circulating sclerostin in disorders of parathyroid gland function
    Aline G Costa
    Department of Medicine, Division of Endocrinology, Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 96:3804-10. 2011
  10. pmc Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Bone Miner Res 26:2317-37. 2011

Research Grants

  1. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John Bilezikian; Fiscal Year: 2009
  2. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John P Bilezikian; Fiscal Year: 2010
  3. TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISM
    John Bilezikian; Fiscal Year: 2007
  4. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John Bilezikian; Fiscal Year: 2007
  5. Targeting Bone Remodeling For the Treatment of Osteoporosis
    John Bilezikian; Fiscal Year: 2007
  6. Treatment of Hypoparathyroidism with Parathyroid Hormone
    John P Bilezikian; Fiscal Year: 2010
  7. PRIMARY HYPERPARATHYROIDISM
    John P Bilezikian; Fiscal Year: 2010
  8. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2000
  9. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 1999
  10. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2001

Detail Information

Publications97

  1. pmc Therapy of osteoporosis in men with teriparatide
    Natalie E Cusano
    Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University in the City of New York, New York, NY 10032, USA
    J Osteoporos 2011:463675. 2011
    ..Thereafter, it is necessary to treat with an antiresorptive drug to maintain, and perhaps increase, densitometric gains. Teriparatide is well tolerated with a good safety profile...
  2. pmc Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series
    Natalie E Cusano
    MD, Department of Medicine, PH 8W 864, Columbia University College of Physicians and Surgeons, 630 West 168th Street, PH8W, Room 864, New York, New York 10032
    J Clin Endocrinol Metab 98:4285-90. 2013
    ..Recovery of hypoparathyroidism years after diagnosis has not previously been reported...
  3. pmc Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations
    Natalie E Cusano
    Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:2734-41. 2013
    ..At diagnosis, patients demonstrate features seen in hypercalcemic primary hyperparathyroidism. Normocalcemic hypoparathyroidism has been discovered after hypocalcemia unmasked after bisphosphonate administration...
  4. pmc The effect of PTH(1-84) on quality of life in hypoparathyroidism
    Natalie E Cusano
    Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:2356-61. 2013
    ..Complaints from hypoparathyroid patients often reflect a reduction in quality of life (QOL), yet few data exist characterizing these complaints or the potential effects of PTH therapy to ameliorate them...
  5. pmc Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism
    Barbara Campolina Silva
    Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:1963-70. 2013
    ....
  6. doi request reprint Primary hyperparathyroidism
    John P Bilezikian
    Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Endocr Pract 18:781-90. 2012
    ..To review primary hyperparathyroidism and the key issues that are relevant to the practicing endocrinologist...
  7. pmc Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety
    Natalie E Cusano
    Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 98:137-44. 2013
    ..PTH may be an effective treatment option for hypoparathyroidism, but long-term data are not available...
  8. ncbi request reprint Parathyroid hormone as an anabolic therapy for women and men
    J P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Endocrinol Invest 28:41-9. 2005
    ..In order to maintain the densitometric gains in bone density with parathyroid hormone, it is important to follow its use with an antiresorptive agent...
  9. pmc Circulating sclerostin in disorders of parathyroid gland function
    Aline G Costa
    Department of Medicine, Division of Endocrinology, Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 96:3804-10. 2011
    ..Sclerostin, a protein encoded by the SOST gene in osteocytes and an antagonist of the Wnt signaling pathway, is down-regulated by PTH administration. Disorders of parathyroid function are useful clinical settings to study this relationship...
  10. pmc Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Bone Miner Res 26:2317-37. 2011
    ..This review, which focuses primarily on hypoparathyroidism in the adult, provides a comprehensive summary of the latest information on this disease...
  11. doi request reprint Regulation of bone mass by serotonin: molecular biology and therapeutic implications
    Gerard Karsenty
    Department of Genetics and Development, Columbia University Medical Center, New York, New York 10032, USA
    Annu Rev Med 62:323-31. 2011
    ..Exploiting these findings in the pharmacological arena led to the demonstration that inhibiting synthesis of gut-derived serotonin could be an effective means to treat low-bone-mass diseases such as osteoporosis...
  12. ncbi request reprint Anabolic therapy for osteoporosis
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032 USA
    Womens Health (Lond Engl) 3:243-53. 2007
    ..Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents has led to ways in which the anabolic window can be expanded...
  13. ncbi request reprint Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features
    J P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Intern Med 257:6-17. 2005
    ..At the NIH workshop, a number of items were highlighted for further investigation such as pharmacological approaches to controlling hypercalcaemia, elevated PTH levels and maintaining bone density...
  14. ncbi request reprint Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, New York, NY 10032, USA
    Curr Osteoporos Rep 4:5-13. 2006
    ..To maintain the gains in bone density with PTH, it is important to follow its use with an antiresorptive agent...
  15. pmc Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop
    John P Bilezikian
    Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Endocrinol Metab 94:335-9. 2009
    ..Asymptomatic primary hyperparathyroidism (PHPT) is a common clinical problem. The purpose of this report is to guide the use of diagnostics and management for this condition in clinical practice...
  16. doi request reprint Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Am J Med 122:S14-21. 2009
    ..Clinical trial extensions of up to 10 years with alendronate and 7 years with risedronate have shown that efficacy is maintained during long-term treatment...
  17. ncbi request reprint Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA E mail
    Curr Osteoporos Rep 6:24-30. 2008
    ..Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents have led to ways in which the anabolic window can be expanded...
  18. ncbi request reprint Asymptomatic primary hyperparathyroidism
    John P Bilezikian
    Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arq Bras Endocrinol Metabol 50:647-56. 2006
    ..In this article, we will review important clinical and diagnostic features of asymptomatic primary hyperparathyroidism as well as considerations for surgical or medical management of the disease...
  19. ncbi request reprint Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century
    John P Bilezikian
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Endocrinol Metab 87:5353-61. 2002
  20. pmc Normocalcemic primary hyperparathyroidism
    John P Bilezikian
    Departamento de Medicina, Columbia University, NY, NY, USA
    Arq Bras Endocrinol Metabol 54:106-9. 2010
    ..In this article, we describe this new entity, normocalcemic primary hyperparathyroidism, a forme fruste of the disease...
  21. ncbi request reprint The potential of parathyroid hormone as a therapy for osteoporosis
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Int J Fertil Womens Med 47:103-15. 2002
    ..In all studies reported to date, PTH appears to be well tolerated. The era of anabolic therapy for osteoporosis is at hand, with PTH being the first to be tested with sufficient rigor to demonstrate its efficacy...
  22. ncbi request reprint Clinical practice. Asymptomatic primary hyperparathyroidism
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York 10032, USA
    N Engl J Med 350:1746-51. 2004
  23. ncbi request reprint Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder
    SUSAN THYS-JACOBS
    St Luke s Roosevelt Hospital Center, Columbia University, New York, New York 10019, USA
    J Clin Endocrinol Metab 92:2952-9. 2007
    ..Recently, it has been suggested that abnormalities in calcium metabolism may be responsible for some affective and somatic symptoms in women with premenstrual syndrome...
  24. ncbi request reprint Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women
    Norman H Bell
    Department of Medicine, Bone, and Mineral Metabolism, Medical University of South Carolina, 114 Doughty Street, PO Box 250775, Charleston, SC 29425, USA
    J Clin Endocrinol Metab 87:2792-7. 2002
    ..We conclude that in postmenopausal African-American women with osteoporosis, alendronate, 10 mg daily for 2 yr, increases BMD at the lumbar spine, hip, and total body and reduces markers of bone remodeling and is well tolerated...
  25. pmc Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis
    Diana M Antoniucci
    Division of Endocrinology, Department of Medicine, University of California, San Francisco, California 94107, USA
    J Clin Endocrinol Metab 92:942-7. 2007
    ..The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated...
  26. ncbi request reprint Anabolic skeletal therapy for osteoporosis
    Monica Girotra
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arq Bras Endocrinol Metabol 50:745-54. 2006
    ..Other potential anabolic therapies for osteoporosis, including other forms of parathyroid hormone, strontium ranelate, growth hormone, and insulin-like growth factor-1, are also reviewed in this article...
  27. ncbi request reprint Anabolic therapy for osteoporosis
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Int J Fertil Womens Med 50:53-60. 2005
    ..This paper describes the activities as known at present of the bisphosphonates and of teriparatide and reviews studies of their use alone and in combination with each other...
  28. ncbi request reprint New anabolic therapies in osteoporosis
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Curr Opin Rheumatol 14:433-40. 2002
    ..Of these, parathyroid hormone has clearly emerged as the most promising treatment at this time...
  29. ncbi request reprint Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Bone Miner Res 17:N2-11. 2002
  30. pmc Dynamic and structural properties of the skeleton in hypoparathyroidism
    Mishaela R Rubin
    College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Bone Miner Res 23:2018-24. 2008
    ..032 +/- 0.028 microm(3)/microm(2)/d, p < 0.0001), were profoundly suppressed in the hypoparathyroid subjects. We conclude that hypoparathyroidism is characterized by markedly unusual structural and dynamic properties of bone...
  31. ncbi request reprint Clinical review: Rare causes of hypercalcemia
    Thomas P Jacobs
    Columbia University Medical Center, 161 Fort Washington Avenue, New York, New York 10032, USA
    J Clin Endocrinol Metab 90:6316-22. 2005
    ..This review considers unusual causes of hypercalcemia that are generally not found in reviews on this subject...
  32. ncbi request reprint Parathyroid hormone as an anabolic skeletal therapy
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Drugs 65:2481-98. 2005
    ..However, in order to maintain the densitometric gains in bone density obtained with PTH, it is important to follow its use with that of an antiresorptive agent...
  33. pmc Three dimensional cancellous bone structure in hypoparathyroidism
    Mishaela R Rubin
    Metabolic Bone Diseases Unit, Department of Medicine, College of Physicians and Surgeons, Columbia University New York, NY, USA
    Bone 46:190-5. 2010
    ..The effect of these structural changes on bone strength remains to be determined...
  34. pmc Human chorionic gonadotropin measurements in parathyroid carcinoma
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, New York 10032, USA
    Eur J Endocrinol 159:469-74. 2008
    ..We investigated whether hCG can distinguish PtCa cancer from benign disease and add prognostic information...
  35. ncbi request reprint Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future
    John P Bilezikian
    Department of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Bone Miner Res 17:N57-67. 2002
    ..helpful and cost effective to warrant their use in all patients who undergo parathyroid surgery? If not, in what patients should they be recommended? (7) What items should be placed on the research agenda for PHPT over the next decade?..
  36. pmc The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years
    Mishaela R Rubin
    Department of Medicine, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032, USA
    J Clin Endocrinol Metab 93:3462-70. 2008
    ..We previously reported that calciotropic indices and bone mineral density (BMD) are stable in untreated patients for up to a decade, whereas after parathyroidectomy, normalization of biochemistries and increases in BMD ensue...
  37. ncbi request reprint The use of parathyroid hormone in the treatment of osteoporosis
    Monica Girotra
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 W 168th Street, New York, NY 10032, USA
    Rev Endocr Metab Disord 7:113-21. 2006
    ..In order to maintain increases in bone density acquired during PTH therapy, it is important to follow its use with an antiresorptive agent...
  38. ncbi request reprint Bone markers--new aspects
    Serge Cremers
    Department of Medicine, Endocrinology, Columbia University, New York, NY 10032, USA
    Clin Lab 54:461-71. 2008
    ..This review discusses some of these new aspects in a perspective that has utility for clinical studies and individual patient care...
  39. ncbi request reprint New anabolic therapies in osteoporosis
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Endocrinol Metab Clin North Am 32:285-307. 2003
    ..Rising expectations that anabolic therapies for osteoporosis will soon play a major role in treating this disease are likely to fuel further studies and the development of even more novel approaches to therapy...
  40. ncbi request reprint Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures
    Ethel S Siris
    Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 88:3482-6. 2003
    ..A call to action is necessary to reduce the human and economic costs associated with this serious and treatable disease...
  41. ncbi request reprint Cystosarcoma phyllodes of the breast occurring in a child with subsequent diagnosis of celiac disease
    Govind Bhagat
    Department of Surgical Pathology and Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Pediatr Gastroenterol Nutr 36:644-6. 2003
  42. ncbi request reprint Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism
    Shonni J Silverberg
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 88:4725-30. 2003
    ..This study also provides evidence that both PTH (1-84) and PTH fragments are produced in parathyroid adenomas and that peripheral metabolism of hormone and fragment does not alter the proportion of bioactive hormone...
  43. ncbi request reprint "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease
    Shonni J Silverberg
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 88:5348-52. 2003
    ....
  44. ncbi request reprint The diagnosis and management of asymptomatic primary hyperparathyroidism
    Shonni J Silverberg
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Nat Clin Pract Endocrinol Metab 2:494-503. 2006
    ....
  45. ncbi request reprint Asymptomatic primary hyperparathyroidism: a medical perspective
    Shonni J Silverberg
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Surg Clin North Am 84:787-801. 2004
    ..These guidelines are elucidated, and new options in the medical therapeutics of primary hyperparathyroidism are discussed...
  46. ncbi request reprint Age as a criterion for surgery in primary hyperparathyroidism
    Shonni J Silverberg
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Am J Med 113:681-4. 2002
  47. ncbi request reprint The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]
    Etah S Kurland
    Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, PH 8 West 864, New York, NY 10032, USA
    Osteoporos Int 15:992-7. 2004
    ..The immediate use of bisphosphonates after teriparatide withdrawal may help to optimize gains in bone density at the lumbar spine...
  48. ncbi request reprint Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism
    Munro Peacock
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Clin Endocrinol Metab 90:135-41. 2005
    ..Cinacalcet rapidly normalizes serum calcium and reduces PTH in patients with primary HPT, and these effects are maintained with long-term treatment. Cinacalcet may be an effective, nonsurgical approach for management of primary HPT...
  49. pmc Application of high-resolution skeletal imaging to measurements of volumetric BMD and skeletal microarchitecture in Chinese-American and white women: explanation of a paradox
    MARCELLA D WALKER
    Columbia University, College of Physicians and Surgeons, New York, New York, USA
    J Bone Miner Res 24:1953-9. 2009
    ..Using the high-resolution technology, the results provide a mechanistic explanation for why Chinese women have fewer hip and forearm fractures than white women...
  50. pmc Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism
    Emily M Stein
    College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Bone 48:557-61. 2011
    ..Vitamin D deficiency is common in patients with primary hyperparathyroidism (PHPT). The presence of low levels of vitamin D may affect the skeletal consequences of PHPT...
  51. ncbi request reprint The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism
    Dolores M Shoback
    Department of Medicine, Veterans Affairs Medical Center, University of California San Francisco, San Francisco, California 94121, USA
    J Clin Endocrinol Metab 88:5644-9. 2003
    ....
  52. ncbi request reprint The anabolic effects of parathyroid hormone therapy
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Clin Geriatr Med 19:415-32. 2003
    ..Ultimately, when the anabolic and catabolic mechanisms of PTH can be clearly distinguished, both mechanistically and in molecular terms, it may be possible to develop PTH analogs that are more purely anabolic...
  53. ncbi request reprint An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma
    Mishaela R Rubin
    College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Clin Chem 53:1470-6. 2007
    ..We investigated whether N-PTH is also overproduced in parathyroid cancer and whether N-PTH concentration is influenced by calcimimetic therapy...
  54. ncbi request reprint Idiopathic osteoporosis in premenopausal women
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, N Y 10032, USA
    Osteoporos Int 16:526-33. 2005
    ..4+/-1.6 ng/ml versus 14.7+/-0.8 ng/ml), although the difference was not statistically significant. These results suggest differences in the pathogenesis of idiopathic osteoporosis in women as compared to men with IOP...
  55. ncbi request reprint Lower insulin-like growth factor-1 concentrations in women with premenstrual dysphoric disorder
    SUSAN THYS-JACOBS
    Division of Endocrinology, Department of Medicine, St Luke s Roosevelt Hospital, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA
    Am J Obstet Gynecol 198:506.e1-8. 2008
    ..Our objective was to measure the cyclic variations in bone turnover across the menstrual cycle in women with and without luteal phase symptoms consistent with severe premenstrual syndrome or premenstrual dysphoric disorder...
  56. ncbi request reprint Osteoporosis in men: pathophysiology and treatment
    Luigi Gennari
    College of Physicians and Surgeons, 630 W 168th Street, New York, NY 10032, USA
    Curr Rheumatol Rep 9:71-7. 2007
    ..This article reviews what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights into causes, pathogenesis, and treatment of osteoporosis in men...
  57. ncbi request reprint Race and diet interactions in the acquisition, maintenance, and loss of bone
    MARCELLA D WALKER
    Division of Endocrinology, Metabolic Bone Disease Unit, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Nutr 138:1256S-60S. 2008
    ..Predictors of aBMD have been reported for African American and American white adults and predictors of aBMD in Chinese American women have recently been studied. Much remains to be studied regarding interactions between race and diet...
  58. pmc Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration
    Mami Ogita
    Department of Medicine, Columbia University, New York, New York 10032, USA
    Endocrinology 149:5713-23. 2008
    ..Estrogens promote proliferation of early osteoblast progenitors but inhibit their differentiation by osteogenic agents such as PTH or BMP-2...
  59. ncbi request reprint Arterial stiffness in mild primary hyperparathyroidism
    Mishaela R Rubin
    Columbia University, College of Physicians and Surgeons, Department of Medicine, PH8 864, 630 West 168th Street, New York, New York 10032, USA
    J Clin Endocrinol Metab 90:3326-30. 2005
    ..05). The diagnosis of primary hyperparathyroidism was therefore an independent predictor of increased AIx, an early measure of arterial stiffness, and the increase was associated with evidence of more active parathyroid disease...
  60. ncbi request reprint Standards for performing DXA in individuals with secondary causes of osteoporosis
    Aliya A Khan
    Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada, and Hanover General Hospital, PA, USA
    J Clin Densitom 9:47-57. 2006
    ..Dual-energy X-ray absorptiometry is a valuable tool in assessing skeletal health in individuals with secondary causes of osteoporosis...
  61. ncbi request reprint Bone density in survivors of childhood cancer
    Jean E Mulder
    Department of Medicine, College of Physicians and Surgeons, New York, NY, USA
    J Clin Densitom 7:432-42. 2004
    ..After a brief review of the processes associated with acquisition of peak bone mass in the young adult, this article examines the impact of cancer and cancer therapy on bone mineral density in survivors of childhood cancer...
  62. ncbi request reprint Osteonecrosis of the jaw--do bisphosphonates pose a risk?
    John P Bilezikian
    College of Physicians and Surgeons, Columbia University, New York, USA
    N Engl J Med 355:2278-81. 2006
  63. ncbi request reprint The role of estrogens in men and androgens in women
    Sundeep Khosla
    Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, 5 194 Joseph, Rochester, MN 55905, USA
    Endocrinol Metab Clin North Am 32:195-218. 2003
    ....
  64. ncbi request reprint Racial differences in the effect of early milk consumption on peak and postmenopausal bone mineral density
    Alexander R Opotowsky
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Bone Miner Res 18:1978-88. 2003
    ..The applicability to other races is unclear. This study of 4316 women found a racial difference in the effect of early milk consumption on bone. Further study is required to evaluate the etiology of this difference...
  65. ncbi request reprint Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence
    Mishaela R Rubin
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Endocrinol Metab 87:4033-41. 2002
  66. doi request reprint Vitamin D toxicity due to a commonly available "over the counter" remedy from the Dominican Republic
    Hyesoo Lowe
    Division of Endocrinology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032, USA
    J Clin Endocrinol Metab 96:291-5. 2011
    ..Hypercalcemia in ambulatory patients is occasionally caused by vitamin D toxicity...
  67. ncbi request reprint Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up study
    Alexander R Opotowsky
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Am J Med 117:169-74. 2004
    ..We analyzed a cohort that was more representative of the overall U.S. population to test the hypothesis that both high and low serum vitamin A concentrations increase the risk of hip fracture...
  68. ncbi request reprint When should a gynecologist refer a patient for specialty care in osteoporosis?
    John P Bilezikian
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Int J Fertil Womens Med 48:132-6; discussion 137-8. 2003
    ....
  69. ncbi request reprint Osteoporosis in men: pathophysiology and treatment
    Luigi Gennari
    College of Physicians and Surgeons, 630 W 168th Street, New York, NY 10032, USA
    Curr Osteoporos Rep 5:22-8. 2007
    ..This article reviews what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights into causes, pathogenesis, and treatment of osteoporosis in men...
  70. ncbi request reprint The cell biology of parathyroid hormone in osteoblasts
    Stavroula Kousteni
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
    Curr Osteoporos Rep 6:72-6. 2008
    ..PTH's ability to orchestrate a dynamic range of signaling cascades that determine osteoblast fate may explain both its catabolic and beneficial actions on the skeleton...
  71. ncbi request reprint PTH-dependent adenylyl cyclase activation in SaOS-2 cells: passage dependent effects on G protein interactions
    Hong Gao
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    J Cell Physiol 193:10-8. 2002
    ..The results suggest that the coupling between the components of the complex may be pivotally important in the differential responsiveness of early and late passage SaOS-2 cells to PTH...
  72. pmc High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone
    X Sherry Liu
    Bone Bioengineering Laboratory, Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
    J Bone Miner Res 25:746-56. 2010
    ..We conclude that microstructural measurements and mechanical parameters of distal tibia can be efficiently derived from HR-pQCT images and provide additional information regarding bone fragility...
  73. ncbi request reprint Summary of the International Society For Clinical Densitometry 2005 Position Development Conference
    Neil Binkley
    Department of Medicine, University of Wisconsin, Madison, WI 53705, USA
    J Bone Miner Res 22:643-5. 2007
  74. pmc Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism
    Ruth Zoehrer
    Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK Social Health Insurance Vienna, Vienna, Austria
    J Clin Endocrinol Metab 93:3484-9. 2008
    ..Hence, there is need to characterize this disorder with particular attention to the skeleton...
  75. ncbi request reprint Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial
    Aliya A Khan
    McMaster University, 331 209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8
    J Clin Endocrinol Metab 89:3319-25. 2004
    ..Significant reductions in bone turnover occur with stable serum calcium and PTH levels. Alendronate may be a useful alternative to parathyroidectomy in asymptomatic PHPT among those with low BMD...
  76. ncbi request reprint Sex steroids, mice, and men: when androgens and estrogens get very close to each other
    John P Bilezikian
    J Bone Miner Res 17:563-6. 2002
  77. ncbi request reprint Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
    Paul D Miller
    FACP, Colorado Center for Bone Research, 3190 South Wadsworth, Suite 250, Lakewood, Colorado 80227, USA
    J Clin Endocrinol Metab 92:3535-41. 2007
    ..Teriparatide (TPTD) [recombinant human PTH(1-34)] given sc once daily transiently increases serum calcium concentrations at 4-6 h after dosing, but its effects on urinary calcium excretion are less well studied...
  78. ncbi request reprint New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging
    Paul Roschger
    Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 4th Department, Hanusch Hospital, Vienna, Austria
    J Bone Miner Res 22:717-23. 2007
    ..A strong correlation between bone turnover status and degree and heterogeneity of mineralization was found. Further studies are needed before we can draw conclusions about fracture risk in this disorder...
  79. ncbi request reprint The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
    Dennis M Black
    Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94105, USA
    N Engl J Med 349:1207-15. 2003
    ..We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone...
  80. ncbi request reprint Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy
    Carolina A M Kulak
    Serviço de Endocrinologia e Metabologia, Hospital de Clinicas, UFPR, Curitiba, PR, Brasil
    Arq Bras Endocrinol Metabol 51:466-71. 2007
    ..In conclusion, patients on AED demonstrate reduced BMD. Among the AED, phenobarbital seems to be the main mediator of low BMD and increases in CTX-I...
  81. ncbi request reprint Bone densitometry in asymptomatic primary hyperparathyroidism
    Paul D Miller
    University of Colorado Health Sciences Center, Colorado Center for Bone Research, Lakewood 80227, USA
    J Bone Miner Res 17:N98-102. 2002
  82. ncbi request reprint Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial
    Elena Ambrogini
    Department of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy
    J Clin Endocrinol Metab 92:3114-21. 2007
    ..It is unclear whether patients with asymptomatic primary hyperparathyroidism (PHPT) do better with parathyroidectomy (PTx) as compared with conservative medical management...
  83. ncbi request reprint Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects
    Stefania Bonadonna
    Department of Medical Sciences, University of Brescia, Brescia, Italy
    Eur J Endocrinol 152:199-205. 2005
    ..Spontaneous parathyroid hormone (PTH) secretory dynamics include tonic and pulsatile components. It is not known how glucocorticoids might alter these secretory dynamics...
  84. ncbi request reprint Clinical use of teriparatide in the real world: initial insights
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, 80227, USA
    Endocr Pract 10:139-48. 2004
    ..To summarize expert opinion regarding clinical application of the recently introduced anabolic agent teriparatide [human parathyroid hormone (1-34)] in treatment of postmenopausal osteoporosis in women, and osteoporosis in men...
  85. ncbi request reprint Mechanisms of anabolic therapies for osteoporosis
    Ernesto Canalis
    Department of Research, Saint Francis Hospital and Medical Center, Hartford, CT 06105 1299, USA
    N Engl J Med 357:905-16. 2007
  86. ncbi request reprint Glucocorticoid-induced osteoporosis: an update
    Gherardo Mazziotti
    Department of Internal Medicine, Spedali Civili, University of Brescia, 25125 Brescia, Italy
    Trends Endocrinol Metab 17:144-9. 2006
    ..Anabolic and alternative therapeutic strategies are currently under investigation in glucocorticoid-induced osteoporosis...
  87. ncbi request reprint What's good for the goose's skeleton is good for the gander's skeleton
    John P Bilezikian
    J Clin Endocrinol Metab 91:1223-5. 2006
  88. ncbi request reprint One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
    Dennis M Black
    Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105, USA
    N Engl J Med 353:555-65. 2005
    ..In the continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in bone mineral density after one year of therapy with parathyroid hormone (1-84)...
  89. pmc Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    J Bone Miner Res 23:1442-8. 2008
    ..The influence of these biochemical changes of type I collagen on bone fracture resistance remains to be studied...
  90. ncbi request reprint Update on osteoporosis therapy
    Joao Lindolfo C Borges
    Universidade Catolica de Brasilia, DF, Brazil
    Arq Bras Endocrinol Metabol 50:755-63. 2006
    ..Despite the effectiveness of therapy with pharmacologic agents, most patients who start therapy do not remain on treatment for more than 1 year...
  91. ncbi request reprint Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs
    Carolina A M Kulak
    Serviço de Endocrinologia e Metabologia, Hospital de Clinicas, Universidade Federal do Parana, Curitiba, PR, Brazil
    Arq Neuropsiquiatr 62:940-8. 2004
    ..38). We conclude that patients on chronic use of AED have alterations in bone metabolism characterized in this study by lower BMD of the lumbar spine and total femur and lower serum concentrations of 25OHD...
  92. pmc Reduced bone mineral density is associated with breast arterial calcification
    Jhansi Reddy
    Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 93:208-11. 2008
    ..The purpose of this study was to determine the association between reduced bone mineral density (BMD) and BAC, which may share a common pathophysiology...
  93. ncbi request reprint Aromatase activity and bone homeostasis in men
    Luigi Gennari
    Department of Internal Medicine, Endocrine Metabolic Sciences, and Biochemistry, University of Siena, Siena 53100, Italy
    J Clin Endocrinol Metab 89:5898-907. 2004
    ....
  94. ncbi request reprint Bone strength in primary hyperparathyroidism
    John P Bilezikian
    Osteoporos Int 14:S113-5; discussion S115-7. 2003
    ..Greater knowledge of the disease should help in understanding anabolic aspects of PTH when it is used as a treatment for osteoporosis...
  95. ncbi request reprint Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference
    Sanford Baim
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Densitom 11:75-91. 2008
    ....
  96. ncbi request reprint Position statements of the International Society for Clinical Densitometry: methodology
    Edward S Leib
    J Clin Densitom 5:S5-10. 2002
    ..Details of the methodology used at the conference are discussed. The following papers explain the results of the discussions and describe the official ISCD positions...
  97. ncbi request reprint Position Development Conference of the International Society for Clinical Densitometry. Vancouver, BC, July 15-17, 2005
    Edward S Leib
    University of Vermont Medicine, 111 Colchester Avenue, Burlington, VT 05401, USA
    J Rheumatol 33:2319-21. 2006
    ..The Official Positions reached at this conference enumerated in this report have been published in The Journal of Clinical Densitometry, and can be found at www.iscd.org...

Research Grants32

  1. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John Bilezikian; Fiscal Year: 2009
    ..This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis. ..
  2. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John P Bilezikian; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: This project is designed to gain new knowledge of the means by which parathyroid hormone, a key regulator of skeletal health, helps to keep bones strong. ..
  3. TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISM
    John Bilezikian; Fiscal Year: 2007
    ..The majority of trainees go on to careers in investigative endocrinology. The Program focuses upon applicants who hold the M.D. or M.D./Ph.D. degrees and have a strong interest in or prior exposure to investigation. ..
  4. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John Bilezikian; Fiscal Year: 2007
    ..This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis. ..
  5. Targeting Bone Remodeling For the Treatment of Osteoporosis
    John Bilezikian; Fiscal Year: 2007
    ....
  6. Treatment of Hypoparathyroidism with Parathyroid Hormone
    John P Bilezikian; Fiscal Year: 2010
    ..This sponsor-investigator expects PTH (1-84) to become the treatment of choice for this orphan disease. ..
  7. PRIMARY HYPERPARATHYROIDISM
    John P Bilezikian; Fiscal Year: 2010
    ..The project is designed to elucidate aspects of this disorder that have been elusive, but which when characterized, will enhance our approach to the therapy of this disorder. ..
  8. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2000
    ....
  9. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 1999
    ....
  10. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2001
    ....
  11. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2002
    ..The results should lead to the establishment of rational recommendations for the management of primary hyperparathyroidism. ..
  12. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2003
    ..The results should lead to the establishment of rational recommendations for the management of primary hyperparathyroidism. ..
  13. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2004
    ..The results should lead to the establishment of rational recommendations for the management of primary hyperparathyroidism. ..
  14. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2009
    ..The project is designed to elucidate aspects of this disorder that have been elusive, but which when characterized, will enhance our approach to the therapy of this disorder. ..
  15. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John Bilezikian; Fiscal Year: 2005
    ..This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis. ..
  16. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2005
    ..The results should lead to the establishment of rational recommendations for the management of primary hyperparathyroidism. ..
  17. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John Bilezikian; Fiscal Year: 2006
    ..This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis. ..
  18. PRIMARY HYPERPARATHYROIDISM
    John Bilezikian; Fiscal Year: 2006
    ..The results should lead to the establishment of rational recommendations for the management of primary hyperparathyroidism. ..